Charles River Laboratories Adds George Llado to Board of Directors
October 16 2020 - 9:15AM
Business Wire
Charles River Laboratories International, Inc. (NYSE: CRL) today
announced the appointment of George Llado, Senior Vice President
and Chief Information Officer of Alexion Pharmaceuticals, Inc., to
its Board of Directors. Mr. Llado’s extensive experience leading
information technology (IT) organizations in the biopharmaceutical
industry will enhance the technological expertise of Charles
River’s Board of Directors. As a member of the Board, he will serve
on the Corporate Governance and Nominating Committee and the
Compensation Committee.
“George Llado’s IT leadership roles with leading global
pharmaceutical and biotechnology companies will benefit Charles
River’s Board as we continue to transform our digital enterprise.
Mr. Llado’s unique view from the client perspective and his
technological expertise will be invaluable as we endeavor to move
our digital strategy forward and enhance our clients’ experience
with real-time connectivity and virtual interface. We also look
forward to leveraging his strategic counsel and insights as we
continue to invest in our IT platforms to drive greater operating
efficiency, access to information, and reinforce our cybersecurity
efforts,” said James C. Foster, Chairman, President and Chief
Executive Officer of Charles River. “George is a dynamic
thought-leader in the technology field, and we are pleased to
welcome his innovative perspectives and industry knowledge to
Charles River’s Board.”
Mr. Llado has more than 30 years of information technology and
cybersecurity experience in the biopharmaceutical industry. As the
Chief Information Officer (CIO) of Alexion Pharmaceuticals, he is
currently responsible for leading its Global Information Technology
organization by developing and implementing innovative technology
and enabling data-driven insights across Alexion’s Research &
Development, Commercial, Manufacturing Operations, and Supply Chain
functions. Prior to joining Alexion in 2015, Mr. Llado was employed
by Merck & Co., Inc. for 25 years in IT positions of increasing
responsibility, most recently as Vice President, Manufacturing and
Supply Chain Information Technology and business-line CIO, for
which he led the planning and development of IT solutions for
Merck’s Manufacturing division. He also held roles as Merck’s Vice
President, Corporate Information Technology and business-line CIO
for its Global Commercial Organization and various corporate
functions. Mr. Llado led the merger integration of Merck and
Schering-Plough across the IT and Shared Business Services
organizations. He is a Board member of the National Center for
Women & Information Technology and Temple University’s Fox
School of Business IT Advisory Board.
“I am pleased to join Charles River’s Board of Directors and
look forward to collaborating with the outstanding team at Charles
River,” said Mr. Llado. “I am excited to bring my background in
technology to help enhance the Company’s digital strategy and
contribute to the future success and growth of this recognized
global leader in early-stage drug research.”
Caution Concerning Forward-Looking
Statements
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements may be identified by the use of
words such as “anticipate,” “believe,” “expect,” “intend,” “will,”
“may,” “estimate,” “plan,” “outlook,” and “project,” and other
similar expressions that predict or indicate future events or
trends or that are not statements of historical matters. Forward
looking statements include statements in this press release
regarding the specific contributions of members of Charles River's
Board of Directors. Forward-looking statements are based on Charles
River’s current expectations and beliefs, and involve a number of
risks and uncertainties that are difficult to predict and that
could cause actual results to differ materially from those stated
or implied by the forward-looking statements. A further description
of these risks, uncertainties, and other matters can be found in
the Risk Factors detailed in Charles River's Annual Report on Form
10-K as filed on February 11, 2020 and the Quarterly Report on Form
10-Q as filed on August 5, 2020, as well as other filings we make
with the Securities and Exchange Commission. Because
forward-looking statements involve risks and uncertainties, actual
results and events may differ materially from results and events
currently expected by Charles River, and Charles River assumes no
obligation and expressly disclaims any duty to update information
contained in this news release except as required by law.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their
research and drug development efforts. Our dedicated employees are
focused on providing clients with exactly what they need to improve
and expedite the discovery, early-stage development and safe
manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services,
visit www.criver.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201016005421/en/
Investor Contact: Todd Spencer Corporate Vice President,
Investor Relations 781.222.6455 todd.spencer@crl.com Media Contact:
Amy Cianciaruso Corporate Vice President, Public Relations
781.222.6168 amy.cianciaruso@crl.com
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Apr 2023 to Apr 2024